Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells.

Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, Hai T, Ron D, Chen W, Trenkle W, Wiestner A, Ye Y.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2200-5. doi: 10.1073/pnas.0807611106. Epub 2009 Jan 22.

2.

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM.

Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.

3.

DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death.

Gozuacik D, Bialik S, Raveh T, Mitou G, Shohat G, Sabanay H, Mizushima N, Yoshimori T, Kimchi A.

Cell Death Differ. 2008 Dec;15(12):1875-86. doi: 10.1038/cdd.2008.121. Epub 2008 Sep 19.

4.

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ.

Blood. 2008 Sep 1;112(5):1923-30. doi: 10.1182/blood-2007-05-092882. Epub 2008 Jun 24.

5.

Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.

Li C, Li R, Grandis JR, Johnson DE.

Mol Cancer Ther. 2008 Jun;7(6):1647-55. doi: 10.1158/1535-7163.MCT-07-2444.

6.

A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells.

Vogler M, Dinsdale D, Sun XM, Young KW, Butterworth M, Nicotera P, Dyer MJ, Cohen GM.

Cell Death Differ. 2008 May;15(5):820-30. doi: 10.1038/cdd.2008.25. Epub 2008 Feb 29.

7.

Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells.

Inoue S, Walewska R, Dyer MJ, Cohen GM.

Leukemia. 2008 Apr;22(4):819-25. doi: 10.1038/leu.2008.1. Epub 2008 Jan 31.

PMID:
18239621
8.

IRE1 signaling affects cell fate during the unfolded protein response.

Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P.

Science. 2007 Nov 9;318(5852):944-9.

10.

Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection.

Hallaert DY, Spijker R, Jak M, Derks IA, Alves NL, Wensveen FM, de Boer JP, de Jong D, Green SR, van Oers MH, Eldering E.

Cell Death Differ. 2007 Nov;14(11):1958-67. Epub 2007 Aug 17.

11.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

12.

Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C.

Cell. 2007 Jun 1;129(5):879-90.

13.

Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

Inoue S, Riley J, Gant TW, Dyer MJ, Cohen GM.

Leukemia. 2007 Aug;21(8):1773-82. Epub 2007 May 24.

PMID:
17525724
14.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC.

Br J Haematol. 2007 Jun;137(5):429-35. Epub 2007 Apr 19.

PMID:
17451408
15.

Structural insights into the degradation of Mcl-1 induced by BH3 domains.

Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, Colman PM.

Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22. Epub 2007 Mar 27.

16.

Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, van Oers MH, van Noesel CJ, Eldering E.

Blood. 2007 Feb 15;109(4):1660-8. Epub 2006 Oct 12.

17.

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

Qin JZ, Xin H, Sitailo LA, Denning MF, Nickoloff BJ.

Cancer Res. 2006 Oct 1;66(19):9636-45.

18.

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa.

Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, Wang CY.

J Biol Chem. 2006 Oct 20;281(42):31440-7. Epub 2006 Aug 23.

19.

Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.

Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ.

Cancer. 2006 Sep 1;107(5):916-24.

20.

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.

Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH.

Blood. 2006 Jun 15;107(12):4907-16. Epub 2006 Feb 28.

Supplemental Content

Support Center